Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAtlantic Lithium Regulatory News (ALL)

Share Price Information for Atlantic Lithium (ALL)

Share Price is delayed by 15 minutes
Get Live Data
16.45    0.00 (0.00%)
Bid:
0.00
Ask:
16.90
Spread: 0.45 (2.736%)
Market Cap: £131.85m
ALL Live PriceLast checked at - London Stock Exchange

Intraday Atlantic Lithium Share Chart

Trading Update

24 Jun 2013 07:00

RNS Number : 6463H
Allocate Software PLC
24 June 2013
 



24 June 2013

 

ALLOCATE SOFTWARE PLC

("Allocate" or "the Company")

 

Full Year Trading Update

 

Allocate Software (AIM: ALL), the leading provider of workforce and compliance optimisation solutions, announces an update on trading for its financial year ended 31 May 2013. The Company's audited results will be announced in the week commencing 22 July 2013.

 

Overview

 

Allocate delivered a very strong second half performance with full year results in line with market expectations for both revenue and EBITA. The Company's cash performance has materially exceeded analysts' expectations due to the continuing transition in the Company's business model to one based more on recurring revenues and due to improvements in working capital.

 

Business

 

The Healthcare business achieved another successful year securing a significant number of agreements for both new products and new customers.

 

UK Healthcare bookings are ahead of revenue because the number of recurring orders secured has been higher than anticipated. The financial effect of this is that cash, deferred revenue and contracted, unbilled orders in hand are higher than anticipated. As a result, this will increase the visibility and predictability of future years' revenue streams.

 

The number of new HealthRoster customers secured by the Company was slightly fewer than the previous financial year but met management's expectations for the second half of the current year. Several of the new customers secured were competitor displacements and HealthRoster renewals continued at the previously recorded 100% renewal rate.

 

The Allocate Cloud, launched in July, has exceeded management original plans with new customers entering agreements in addition to existing customers who have already licensed the software, committing to the Cloud service. A further positive impact of this performance is on cash flow, as noted above.

 

Sales of the Medics products enjoyed a good year with a number of new customers signing contracts and a high renewal rate of annual subscriptions. Multiyear renewals have been secured with substantially more customers than anticipated demonstrating high levels of customer satisfaction. A further beneficial impact of the multiyear renewals is on cash flow, as noted above.

 

The migration from HealthRoster V9 to V10 continues in line with management plans. Customers that have migrated are located primarily in the UK, along with customers in the USA and Australia.

 

The Defence business had a productive year securing a major contract with Royal Australian Airforce as well as securing a series of important professional services contract extensions.

 

The Maritime business had a successful year securing a new offshore services customer in addition to closing a number of important follow on licence and services contract extensions.

 

Ian Bowles, Chief Executive Officer of Allocate commented: "2012 was a very important year for Allocate. We launched HealthRoster V10, our most important product for many years and we launched the Allocate Cloud, a completely new HealthRoster service that has been extremely well received by our customers and prospects. Sales of our Medics portfolio of applications exceeded management plans and we continued to secure our 100% renewal rate on HealthRoster. Both the Defence and Maritime businesses again performed solidly.

 

"At the same time as delivering revenue in line with expectations we continued our transition to a business with higher recurring and deferred revenues. Although revenue growth has been masked by both a large order in the prior year and the move to higher recurring and deferred revenues, billings and cash show more significant growth and more fairly reflect the true underlying progress that Allocate has achieved this year.

 

"We remain well placed to support the broader healthcare market in general and specifically the NHS in its goals of improving patient care whilst driving improvements in efficiency."

 

Enquiries:

 

Allocate Software plc

Ian Bowles - Chief Executive Officer

Chris Gale - Chief Financial Officer

Martin Jeffries - Marketing Director

 

Tel: +44 (0) 20 7355 5555

Numis Securities

Nominated adviser - Michael Meade / Simon Willis/ Richard Thomas

Corporate Broking - James Black

 

Tel: +44 (0) 20 7260 1000

Gable Communications

Justine James / John Bick

 

Tel: +44 (0) 20 7193 7463

M: +44 (0) 7525 324431

 

About Allocate Software plc

Allocate Software plc is the leading workforce optimisation software applications provider for world-wide organisations with large, multi-skilled workforces. With a blue chip client base spanning the public and private sector, its key vertical markets include: Healthcare and Defence.

 

At the core of the business is Allocate's workforce optimisation software, which organisations use to deploy the right people with the right skills, to the right place at the right time. Headquartered in London, Allocate provides services and support to its increasing international customer base through regional offices in the UK, Sweden, USA, Australia and Malaysia.

 

Allocate is quoted on the London Stock Exchange (AIM: ALL). For further information please visit www.allocatesoftware.com.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUAVBRONANUAR
Date   Source Headline
30th Mar 20237:00 amRNSConference Attendance
24th Mar 20237:00 amRNSCorporate Update - Director/PDMR Shareholding
22nd Mar 20237:00 amRNSDefinitive Feasibility Study Project Update
20th Mar 20237:00 amRNS2023 Exploration and Resource Programmes Update
20th Mar 20237:00 amRNSDirector/PDMR Shareholding
17th Mar 20237:05 amRNSInvestor Presentation
17th Mar 20237:00 amRNSHolding(s) in Company
15th Mar 20237:00 amRNSCorporate Update and Half-year Financial Report
9th Mar 20238:15 amRNSRestoration - Atlantic Lithium Limited
9th Mar 20238:00 amRNSResponse to Online Report & Restoration of Trading
8th Mar 20234:15 pmRNSSuspension - Atlantic Lithium Limited
1st Mar 20238:00 amRNSResults of Extraordinary General Meeting
21st Feb 20237:00 amRNSCommunications Update - Conference Attendance
17th Feb 20237:00 amRNSExpression of Interest - Investment by MIIF
13th Feb 20239:00 amRNSRicca Resources - Pre-IPO Placement
3rd Feb 20238:00 amRNSCorporate Communication Update Mining Indaba 2023
1st Feb 20237:00 amRNSEwoyaa Mineral Resource increases to 35.3Mt
31st Jan 20237:00 amRNSNotice of Extraordinary General Meeting
30th Jan 20237:00 amRNSQuarterly Activities and Cash Flow Report Dec 2022
20th Jan 20237:00 amRNSCorporate Update – 2023 OTCQX Best 50 - ALLIF
12th Jan 20237:00 amRNSFinal Assay Results and New High-Grade pegmatites
30th Dec 20228:00 amRNSCorporate Update Change of terms for Share Options
13th Dec 20227:00 amRNSPrimero awarded FEED Contract for Ewoyaa Lithium
5th Dec 20227:00 amRNSCommunication Update - LSE Investor Webinar
30th Nov 20227:15 amRNSCorporate Update - Result of 2022 AGM
29th Nov 20227:00 amRNSHigh-Grade Drill Results - Highest Grade to Date
28th Nov 20227:00 amRNSAppointment of Alternate Director
28th Nov 20227:00 amRNSCommencement of COO and Issue of Options
22nd Nov 20227:00 amRNSTR1 Notification of Major Holdings
16th Nov 20227:00 amRNSCorporate Update - Mines & Money London 2022
9th Nov 20227:38 amRNSSignificant Potential for Resource Upgrades
2nd Nov 20227:00 amRNSHighest Reported Grade to Date of 4.52% Li2O
31st Oct 20227:00 amRNSNotice of AGM
27th Oct 20227:10 amRNSAppointment of Chief Operating Officer
27th Oct 20227:05 amRNSQuarterly Activities and Cash Flow Report
27th Oct 20227:00 amRNSInvestor Presentation for Webinar
21st Oct 20227:00 amRNSCorporate Communication Update - Investor Webinar
20th Oct 20227:00 amRNSOngoing High-Grade Lithium Intersections at Ewoyaa
13th Oct 20227:00 amRNSMining Licence Application Lodged for Ewoyaa
12th Oct 20227:00 amRNSCorporate Update - Conference Attendance
30th Sep 20227:30 amRNSCorporate Update – 2022 Annual Financial Report
28th Sep 202210:00 amRNSPiedmont Partner Atlantic Lithium Completes PFS
26th Sep 202210:00 amRNSASX Listing – Commencement of Trading
22nd Sep 20227:00 amRNSRobust Ewoyaa Pre-Feasibility Study
21st Sep 20227:01 amRNSASX Listing – Admission to Official List
19th Sep 20227:00 amRNSCorporate Update - Issue of Equity / PCA Dealings
16th Sep 20222:00 pmRNSTR1 Notification of Significant Shareholding
8th Sep 202210:00 amRNSCorporate Update Dual Listing – Close of ASX Offer
30th Aug 202212:00 pmRNSCorporate Communication Update - Africa Down Under
30th Aug 202210:00 amRNSLodgement of Dual Listing Replacement Prospectus

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.